Search Results - "YOKOYAMA, Takuhei"

LSR Antibody Therapy Inhibits Ovarian Epithelial Tumor Growth by Inhibiting Lipid Uptake by Hiramatsu, Kosuke, Serada, Satoshi, Enomoto, Takayuki, Takahashi, Yusuke, Nakagawa, Satoshi, Nojima, Satoshi, Morimoto, Akiko, Matsuzaki, Shinya, Yokoyama, Takuhei, Takahashi, Tsuyoshi, Fujimoto, Minoru, Takemori, Hiroshi, Ueda, Yutaka, Yoshino, Kiyoshi, Morii, Eiichi, Kimura, Tadashi, Naka, Tetsuji

“…Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy, but it still lacks effective treatment options. In this study, we utilized proteomic…”
Get full text

Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer by Brill, Ethan, Yokoyama, Takuhei, Nair, Jayakumar, Yu, Minshu, Ahn, Yeong-Ran, Lee, Jung-Min

“…PARP inhibitors (PARPi) have been effective in high-grade serous ovarian cancer (HGSOC), although clinical activity is limited against wild type HGSOC. The…”
Get full text

Biomarkers for Screening, Diagnosis, and Monitoring of Ovarian Cancer by KOBAYASHI, Eiji, UEDA, Yutaka, MATSUZAKI, Shinya, YOKOYAMA, Takuhei, KIMURA, Toshihiro, YOSHINO, Kiyoshi, FUJITA, Masami, KIMURA, Tadashi, ENOMOTO, Takayuki

“…Serum tumor markers have a major role in the screening, diagnosis, and monitoring of most of the gynecologic cancers. Ovarian cancer is one of the deadliest of…”
Get full text

Plasma membrane proteomics identifies bone marrow stromal antigen 2 as a potential therapeutic target in endometrial cancer by Yokoyama, Takuhei, Enomoto, Takayuki, Serada, Satoshi, Morimoto, Akiko, Matsuzaki, Shinya, Ueda, Yutaka, Yoshino, Kiyoshi, Fujita, Masami, Kyo, Satoru, Iwahori, Kota, Fujimoto, Minoru, Kimura, Tadashi, Naka, Tetsuji

“…This report utilizes a novel proteomic method for discovering potential therapeutic targets in endometrial cancer. We used a biotinylation‐based approach for…”
Get full text

Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma by Matsuo, Koji, Omatsu, Kohei, Ross, Malcolm S, Johnson, Marian S, Yunokawa, Mayu, Klobocista, Merieme M, Im, Dwight D, Bush, Stephen H, Ueda, Yutaka, Takano, Tadao, Blake, Erin A, Hasegawa, Kosei, Baba, Tsukasa, Shida, Masako, Satoh, Shinya, Yokoyama, Takuhei, Machida, Hiroko, Adachi, Sosuke, Ikeda, Yuji, Iwasaki, Keita, Miyake, Takahito M, Yanai, Shiori, Nishimura, Masato, Nagano, Tadayoshi, Takekuma, Munetaka, Takeuchi, Satoshi, Pejovic, Tanja, Shahzad, Mian MK, Ueland, Frederick R, Kelley, Joseph L, Roman, Lynda D

“…Abstract Background To examine recurrence patterns in women with stage I uterine carcinosarcoma (UCS) stratified by adjuvant therapy pattern. Methods We…”
Get full text

Tumor characteristics and outcome of uterine carcinosarcoma in women aged ≥80 years by Matsuo, Koji, Ross, Malcolm S., Yunokawa, Mayu, Johnson, Marian S., Machida, Hiroko, Omatsu, Kohei, Klobocista, Merieme M., Im, Dwight D., Satoh, Shinya, Baba, Tsukasa, Ikeda, Yuji, Bush, Stephen H., Hasegawa, Kosei, Blake, Erin A., Takekuma, Munetaka, Shida, Masako, Nishimura, Masato, Adachi, Sosuke, Pejovic, Tanja, Takeuchi, Satoshi, Yokoyama, Takuhei, Ueda, Yutaka, Iwasaki, Keita, Miyake, Takahito M., Yanai, Shiori, Nagano, Tadayoshi, Takano, Tadao, Shahzad, Mian MK, Ueland, Frederick R., Kelley, Joseph L., Roman, Lynda D.

“…To examine clinico-pathological characteristics and outcomes of uterine carcinosarcoma (UCS) in women aged ≥80 years. This is a secondary analysis of a…”
Get full text

Clinical utility of CA-125 in the management of uterine carcinosarcoma by Matsuo, Koji, Ross, Malcolm S, Yunokawa, Mayu, Johnson, Marian S, Machida, Hiroko, Omatsu, Kohei, Klobocista, Merieme M, Im, Dwight D, Satoh, Shinya, Baba, Tsukasa, Ikeda, Yuji, Bush, Stephen H, Hasegawa, Kosei, Blake, Erin A, Takekuma, Munetaka, Shida, Masako, Nishimura, Masato, Adachi, Sosuke, Pejovic, Tanja, Takeuchi, Satoshi, Yokoyama, Takuhei, Ueda, Yutaka, Iwasaki, Keita, Miyake, Takahito M, Yanai, Shiori, Nagano, Tadayoshi, Takano, Tadao, Shahzad, Mian Mk, Ueland, Frederick R, Kelley, Joseph L, Roman, Lynda D

“…KCI Citation Count: 2…”
Get full text

Endometrial carcinoma: better prognosis for asymptomatic recurrences than for symptomatic cases found by routine follow-up by Ueda, Yutaka, Enomoto, Takayuki, Egawa-Takata, Tomomi, Miyatake, Takashi, Yoshino, Kiyoshi, Fujita, Masami, Matsuzaki, Shinya, Yokoyama, Takuhei, Miyoshi, Yukari, Kimura, Tadashi

“…Background The aim of this study was to determine if there is a prognostic value for the presence of symptoms at the time of recurrence detection in surgically…”
Get full text

Prediction, based on resection margins, of long-term outcome of cervical intraepithelial neoplasia 3 treated by Shimodaira-Taniguchi conization by Miyoshi, Yukari, Miyatake, Takashi, Ueda, Yutaka, Morimoto, Akiko, Yokoyama, Takuhei, Matsuzaki, Shinya, Kimura, Toshihiro, Yoshino, Kiyoshi, Fujita, Masami, Ohashi, Hiroshi, Morii, Eiichi, Enomoto, Takayuki, Kimura, Tadashi

“…Purpose The aim of the present study was to analyze the long-term outcome of cervical intraepithelial neoplasia 3 (CIN 3) after treatment with the…”
Get full text

Recurrent endometrial carcinoma: prognosis for patients with recurrence within 6 to 12 months is worse relative to those relapsing at 12 months or later by Miyake, Takahito, MD, PhD, Ueda, Yutaka, MD, PhD, Egawa-Takata, Tomomi, MD, Matsuzaki, Shinya, MD, Yokoyama, Takuhei, MD, Miyoshi, Yukari, MD, Kimura, Toshihiro, MD, PhD, Yoshino, Kiyoshi, MD, PhD, Fujita, Masami, MD, PhD, Yamasaki, Masato, MD, PhD, Enomoto, Takayuki, MD, PhD, Kimura, Tadashi, MD, PhD

“…Objective We evaluated association of prognosis of endometrial carcinoma patients and treatment-free intervals (TFIs). Study Design We compared the…”
Get full text

Mid-second trimester measurement of fetal nasal bone length in the Japanese population by Kanagawa, Takeshi, Fukuda, Hirotsugu, Kinugasa, Yukiko, Son, Mihyon, Shimoya, Koichiro, Murata, Yuji, Yokoyama, Takuhei, Hashimoto, Hiroyuki, Isaka, Shigeyuki, Nagamatsu, Masaaki

“…Aim:  We carried out a preliminary study to compare the nasal bone length (NBL) and biparietal diameter/NBL (BPD/NBL) ratio between the Japanese and white…”
Get full text

Apoptosis is augmented in high-grade serous ovarian cancer by the combined inhibition of Bcl-2/Bcl-xL and PARP by Yokoyama, Takuhei, Kohn, Elise C, Brill, Ethan, Lee, Jung-Min

“…The aim of our study was to evaluate possible synergistic cytotoxic effects of the combination treatment with the BH3-mimetic ABT-263 and the PARP inhibitor…”
Get full text

Abstract 264: The cell cycle checkpoint kinase 1/2 inhibitor, LY2606368 with PARP inhibition results in synergistic cytotoxicity in high-grade serous ovarian cancer (HGSOC) at lower than physiologically administered concentrations by Ahn, Yeong-ran, Yokoyama, Takuhei, Yu, Minshu, Gordon, Nicolas, Kohn, Elise C., Lee, Jung-min

“…Abstract Background: Chk1/2 are major cell cycle regulators in p53-deficient tumors, such as HGSOC. Chk1 plays a critical role in DNA repair, facilitating the…”
Get full text

Abstract 264: The cell cycle checkpoint kinase 12 inhibitor, LY2606368 with PARP inhibition results in synergistic cytotoxicity in high-grade serous ovarian cancer (HGSOC) at lower than physiologically administered concentrations by Ahn, Yeong-ran, Yokoyama, Takuhei, Yu, Minshu, Gordon, Nicolas, Kohn, Elise C, Lee, Jung-min

“…Background: Chk12 are major cell cycle regulators in p53-deficient tumors, such as HGSOC. Chk1 plays a critical role in DNA repair, facilitating the…”
Get full text

Abstract 4410: LSR promotes ovarian cancer cell growth following the activation of β-oxidation and its antibody inhibits lipid catabolism by Hiramatsu, Kosuke, Serada, Satoshi, Enomoto, Takayuki, Yokoyama, Takuhei, Takahashi, Yusuke, Fujimoto, Minoru, Yoshino, Kiyoshi, Kimura, Tadashi, Naka, Tetsuji

“…Abstract Ovarian cancer is the most lethal gynecologic malignancy; thus developing new treatment options is urgently required. Molecular targeted therapies for…”
Get full text

Abstract 5363: Navitoclax (Nav) and BMN 673 yield cytotoxicity with lower doses than used for single agents in high-grade serous ovarian cancer (HGSOC) by Yokoyama, Takuhei, Gordon, Nicolas, Yu, Minshu, Kohn, Elise C., Lee, Jung-Min

“…Abstract Background: The apoptosis inhibitor Bcl-xL is upregulated in recurrent ovarian cancer (OvCa). Modest clinical activity with Nav, a Bcl-2/Bcl-xL…”
Get full text

Annexin A4‐conferred platinum resistance is mediated by the copper transporter ATP7A by Matsuzaki, Shinya, Enomoto, Takayuki, Serada, Satoshi, Yoshino, Kiyoshi, Nagamori, Shushi, Morimoto, Akiko, Yokoyama, Takuhei, Kim, Ayako, Kimura, Toshihiro, Ueda, Yutaka, Fujita, Masami, Fujimoto, Minoru, Kanai, Yoshikatsu, Kimura, Tadashi, Naka, Tetsuji

“…Although platinum drugs are often used for the chemotherapy of human cancers, platinum resistance is a major issue and may preclude their use in some cases. We…”
Get full text

Significance of venous thromboembolism in women with uterine carcinosarcoma by Matsuo, Koji, Ross, Malcolm S., Im, Dwight D., Klobocista, Merieme M., Bush, Stephen H., Johnson, Marian S., Takano, Tadao, Blake, Erin A., Ikeda, Yuji, Nishimura, Masato, Ueda, Yutaka, Shida, Masako, Hasegawa, Kosei, Baba, Tsukasa, Adachi, Sosuke, Yokoyama, Takuhei, Satoh, Shinya, Machida, Hiroko, Yanai, Shiori, Iwasaki, Keita, Miyake, Takahito M., Takeuchi, Satoshi, Takekuma, Munetaka, Nagano, Tadayoshi, Yunokawa, Mayu, Pejovic, Tanja, Omatsu, Kohei, Shahzad, Mian M.K., Kelley, Joseph L., Ueland, Frederick R., Roman, Lynda D.

“…To identify risk factors for venous thromboembolism (VTE) and to examine the association of VTE and survival in women with uterine carcinosarcoma. This…”
Get full text

Proposal for a Risk-Based Categorization of Uterine Carcinosarcoma by Matsuo, Koji, Takazawa, Yutaka, Ross, Malcolm S., Elishaev, Esther, Yunokawa, Mayu, Sheridan, Todd B., Bush, Stephen H., Klobocista, Merieme M., Blake, Erin A., Takano, Tadao, Baba, Tsukasa, Satoh, Shinya, Shida, Masako, Ikeda, Yuji, Adachi, Sosuke, Yokoyama, Takuhei, Takekuma, Munetaka, Yanai, Shiori, Takeuchi, Satoshi, Nishimura, Masato, Iwasaki, Keita, Johnson, Marian S., Yoshida, Masayuki, Hakam, Ardeshir, Machida, Hiroko, Mhawech-Fauceglia, Paulette, Ueda, Yutaka, Yoshino, Kiyoshi, Kajiwara, Hiroshi, Hasegawa, Kosei, Yasuda, Masanori, Miyake, Takahito M., Moriya, Takuya, Yuba, Yoshiaki, Morgan, Terry, Fukagawa, Tomoyuki, Pejovic, Tanja, Nagano, Tadayoshi, Sasaki, Takeshi, Richmond, Abby M., Post, Miriam D., Shahzad, Mian M. K., Im, Dwight D., Yoshida, Hiroshi, Enomoto, Takayuki, Omatsu, Kohei, Ueland, Frederick R., Kelley, Joseph L., Karabakhtsian, Rouzan G., Roman, Lynda D.

“…Purpose To propose a categorization model of uterine carcinosarcoma (UCS) based on tumor cell types (carcinoma and sarcoma) and sarcoma dominance. Methods This…”
Get full text

Tumor characteristics and survival outcomes of women with tamoxifen-related uterine carcinosarcoma by Matsuo, Koji, Ross, Malcolm S, Bush, Stephen H, Yunokawa, Mayu, Blake, Erin A, Takano, Tadao, Ueda, Yutaka, Baba, Tsukasa, Satoh, Shinya, Shida, Masako, Ikeda, Yuji, Adachi, Sosuke, Yokoyama, Takuhei, Takekuma, Munetaka, Takeuchi, Satoshi, Nishimura, Masato, Iwasaki, Keita, Yanai, Shiori, Klobocista, Merieme M, Johnson, Marian S, Machida, Hiroko, Hasegawa, Kosei, Miyake, Takahito M, Nagano, Tadayoshi, Pejovic, Tanja, Shahzad, Mian MK, Im, Dwight D, Omatsu, Kohei, Ueland, Frederick R, Kelley, Joseph L, Roman, Lynda D

“…Abstract Objective To examine tumor characteristics and survival outcome of women with uterine carcinosarcoma who had a history of tamoxifen use. Methods This…”
Get full text